Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies

Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies

Abstract B cell receptor (BCR) signaling is involved in the pathogenesis of B cell malignancies. Activation of BCR signaling promotes the survival and proliferation of malignant B cells. Bruton tyrosine kinase (BTK) is a key component of BCR signaling, establishing BTK as an important therapeutic ta...

Full description

Bibliographic Details
Main Authors: Danling Gu, Hanning Tang, Jiazhu Wu, Jianyong Li, Yi Miao
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Journal of Hematology & Oncology
Subjects:
BTK
B cell malignancies
Ibrutinib
C481 mutations
Non-covalent inhibitors
Online Access:https://doi.org/10.1186/s13045-021-01049-7

Internet

https://doi.org/10.1186/s13045-021-01049-7

Similar Items